Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023

Chiong E 1 , Murphy DG 2 , Buchan N 3 , Chen K 4 , Chen SS 5 , Chua MLK 6 Show all authors , Hamid AR 7 , Kanesvaran R 8 , Khochikar M 9 , Letran J 10 , Lojanapiwat B 11 , Mallik I 12 , Ng CF 13 , Ong TA 14 , Poon DMC 15 , Pu YS 16 , Saad M 17 , Schubach K 18 , Takahara K 19 , Tey J 20 , Thang SP 21 , Toh PC 1 , Türkeri L 22 , Vinh NT 23 , Williams S 18 , Ye D 24 , ANZUP Cancer Trials Group , Davis ID 25

Affiliations 

  • 1 Department of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore
  • 2 Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia
  • 3 Department of Urology, Christchurch Public Hospital, Christchurch, New Zealand
  • 4 Department of Urology, Singapore General Hospital, Singapore, Singapore
  • 5 Department of Nursing, Tan Tock Seng Hospital, Singapore, Singapore
  • 6 Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore
  • 7 Department of Urology, Faculty of Medicine Universitas Indonesia - CiptoMangunkusumo Hospital, Jakarta, Indonesia
  • 8 Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  • 9 Department of Urology/Uro-oncology, Ushakal Abhinav Institute of Medical Sciences, Sangli, India
  • 10 Department of Urology, Chinese General Hospital and Medical Center, Manila, Philippines
  • 11 Department of Surgery, Chiang Mai University, Chiang Mai, Thailand
  • 12 Department of Radiation Oncology, Tata Medical Center, Kolkata, India
  • 13 SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China
  • 14 Department of Surgery, Universiti Malaya, Kuala Lumpur, Malaysia
  • 15 Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
  • 16 Department of Urology, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan
  • 17 Department of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
  • 18 Monash University, Melbourne, Australia, Eastern Health, Melbourne, Australia
  • 19 Department of Urology, Fujita Health University, Toyoake, Japan
  • 20 Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore, Singapore
  • 21 Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore
  • 22 Department of Urology, Altunizade Hospital, Acibadem M.A. Aydinlar University, Istanbul, Turkey
  • 23 Department of Urology, Binh Dan Hospital, Ho Chi Minh City, Vietnam
  • 24 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
  • 25 Lifehouse, Camperdown, Australia
Asia Pac J Clin Oncol, 2024 Aug;20(4):481-490.
PMID: 38628049 DOI: 10.1111/ajco.14064

Abstract

AIM: The aim of the third Asia-Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2023) was to discuss the application in the Asia-Pacific (APAC) region of consensus statements from the 4th Advanced Prostate Cancer Consensus Conference (APCCC 2022).

METHODS: The one-day meeting in July 2023 brought together 27 experts from 14 APAC countries. The meeting covered five topics: (1) Intermediate- and high-risk and locally advanced prostate cancer; (2) Management of newly diagnosed metastatic hormone-sensitive prostate cancer; (3) Management of non-metastatic castration-resistant prostate cancer; (4) Homologous recombination repair mutation testing; (5) Management of metastatic castration-resistant prostate cancer. Pre- and post-symposium polling gathered APAC-specific responses to APCCC consensus questions and insights on current practices and challenges in the APAC region.

RESULTS: APAC APCCC highlights APAC-specific considerations in an evolving landscape of diagnostic technologies and treatment innovations for advanced prostate cancer. While new technologies are available in the region, cost and reimbursement continue to influence practice significantly. Individual patient considerations, including the impact of chemophobia on Asian patients, also influence decision-making.

CONCLUSION: The use of next-generation imaging, genetic testing, and new treatment combinations is increasing the complexity and duration of prostate cancer management. Familiarity with new diagnostic and treatment options is growing in the APAC region. Insights highlight the continued importance of a multidisciplinary approach that includes nuclear medicine, genetic counseling, and quality-of-life expertise. The APAC APCCC meeting provides an important opportunity to share practice and identify APAC-specific issues and considerations in areas of low evidence where clinical experience is growing.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications